logo
  Join        Login             Stock Quote

Abbott (ABT), Sucampo (SCMP) Say Chronic Constipation Medicine Launched In Japan

 November 26, 2012 07:47 AM
 


(By Balachander) Abbott Laboratories (NYSE: ABT) and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) announced the launch of AMITIZA in Japan, a prescription medicine to treat chronic constipation not caused by organic diseases.

"AMITIZA may significantly advance the treatment of chronic constipation and will be the only prescription option available in Japan for this condition," the companies noted.

The U.S.-based companies said AMITIZA was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in June. The medicine is approved in the United States for the treatment of two constipation-related indications, and in Switzerland and the United Kingdom for one constipation-related indication.

[Related -AbbVie Inc (ABBV): What To Watch In Q4 Results?]

The medicine has a unique mode of action that induces natural bowel movement frequency that is more in line with normal bowel habits, Abbott and Sucampo said. Chronic constipation is one of the most common digestive condition complaints.

Abbott will promote and distribute AMITIZA in Japan under the terms of the 2009 license, commercialization and supply agreement with Sucampo. SPL submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market AMITIZA in September 2010. 

On Friday, ABT shares ended at $64.47, while SCMP shares closed at $4.97.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageWinter is Coming! Here's My Favorite Seasonal Trade

Over the years, I've been successful trading weather patterns as they relate to commodities such as crude read on...

article imageHow To Avoid 5 Common Investing Mistakes

When it comes to successful investing, the field of behavioral finance has shown that sometimes the worst read on...

article imageSector Detector: Bulls Go Down Swinging, Refusing To Give Up Much Ground

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down read on...

article imageThe Bumpy Road Ahead To Policy Normalization

When the dust clears from tomorrow’s Fed announcement, the crowd’s expecting that the slow but persistent read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.